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ABSTRACT
A Lateral Flow Assay to detect cryptococcal antigen (CrAg® LFA) in serum and 
cerebrospinal fluid for the rapid diagnosis of cryptococcosis was evaluated. A retrospective 
validation was performed. Sensitivity and specificity of the CrAg® LFA was 100%. High 
concordance (kappa index=1.0) between Cryptococcal Antigen Latex Agglutination System 
(CALAS®) and CrAg® LFA was observed. CrAg® LFA showed higher analytical sensitivity 
for detecting low concentrations of cryptococcal antigen.
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Cryptococcal meningitis primarily occurs in AIDS patients and especially in 
those with CD4 cell counts less than 100 cells/µL, and continues causing high 
mortality and morbidity, especially in resource-limited countries1. In Colombia, 
as in other Latin American countries, access to antiretroviral therapy (ART) may 
be limited. As a result, cryptococcosis and other opportunistic infections (OIs) are 
major causes of mortality in people living with HIV and AIDS (PLWHA)1. Early 
and rapid diagnosis of cryptococcosis reduces the risk of mortality and morbidity 
and the development of severe disease by facilitating prompt and timely treatment2. 
Detection of cryptococcal antigen in serum and cerebrospinal fluid (CSF) has 
proven to be a highly sensitive (93-100%) and specific (93-98%) method for 
diagnosing cryptococcosis3. In this study, we compared two cryptococcal antigen 
tests, one dipstick sandwich immunochromatographic assay developed by IMMY® 
(Immuno-Mycologics, Norman, Oklahoma, USA) and a Cryptococcal Antigen Latex 
Agglutination System (CALAS®) developed by Meridian Bioscience (Cincinnati, 
Ohio, USA).
A retrospective validation study of the CrAg® LFA test was conducted in the 
Medical Mycology laboratory of a private research institution, the Corporación 
para Investigaciones Biológicas (CIB), in Medellín, Colombia. Serum and CSF 
samples from patients with or without diagnosis of cryptococcosis were randomly 
selected from a collection of biological samples stored in the CIB’s biobank. All 
samples were coded and analyzed blindly. Diagnosis of cryptococcosis was based 
on the EORTC/MSG definitions4. A case was considered proven if Cryptococcus 
was isolated from blood, tissue, sterile fluids or respiratory specimens, or if there 
was a positive antigen test in serum or CSF using CALAS® 4. Sensitivity and 
specificity of the CrAg® LFA were calculated using microbiological criteria for 
diagnosing cryptococcosis. The capacity to perform the diagnosis of cryptococcosis 
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between CrAg® LFA and CALAS® was compared, and the 
ability to quantify Cryptococcus antigens in CSF was also 
evaluated for each test5. Positive antigen samples were 
diluted initially 1:4, followed by a two-fold serial dilution 
up to 1:16,184 (dilutions are shown in Figure 1). CrAg® 
LFA and CALAS® were performed in parallel using the 
same sample’s dilutions.A total of 51 CSF and 32 serum 
samples from 83 patients were tested. Of these, 31 CSF 
and 15 sera were from proven cryptococcal cases and the 
remaining samples were from patients who did not have 
cryptococcosis (Figure 2).
Sensitivity and specificity of CrAg® LFA in sera were 
both 100% (95% confidence interval [95% CI] = 97-100%). 
For the CSF, both sensitivity and specificity were also 100% 
(95% CI = 98-100% for sensitivity, and 95% CI = 97-100% 
for specificity). In the two types of sample (serum and 
CSF), the concordance between CrAg® LFA and CALAS® 
was 1.0 (kappa index, 95% CI = 1.0-1.0) (Table 1). When 
we compared the capacity to detect different Cryptococcus 
antigens levels between CrAg® LFA and CALAS® in CSF, 
CrAg® LFA demonstrated higher sensitivity to detect lower 
concentrations of antigen (Figure 1). 
Results of this study showed that both serum and CSF 
specimens tested with the CrAg® LFA were 100% sensitive 
and specific. This is consistent with the reported sensitivity 
and specificity of this LFA in other laboratories around the 
world6-10. The CrAg® LFA was also able to detect lower 
concentrations of antigens in CSF as compared with the 
CALAS® assay, a finding that has been previously reported9.
The CrAg® LFA test is a simple technique that can be 
easily performed in any laboratory; additionally, storage and 
incubation of reagents are performed at room temperature, 
and the specimen does not require pre-treatment with 
pronase or any other additional  step.
A limitation of this study was that we were unable 
to access complete information from the clinical records 
on associated complications and mortality. Additionally, 
the number of samples that were used in this study was 
small. For the CrAg® LFA, two independent technicians 
performed the readings and no discordant results were 
found, although, for the latex agglutination test, only one 
technician with extensive training and expertise performed 
the readings. These diagnostic methods are supported by 
multiple validations with results similar to those observed 
in this study6-10.
In summary, the study presented here evaluated the 
CrAg® LFA test for detection of cryptococcosis using serum 
and CSF in a specialized laboratory in Medellín, Colombia. 
This test is relatively cheap and readily available, requires 
minimal laboratory steps and can be completed in less than 
15 minutes using basic supplies. It shows high sensitivity, 
specificity, and concordance with currently CrAg tests used 
in the diagnosis of cryptococcosis. Additionally, the CrAg® 
Figure 2 - Flowchart of serum and CSF samples analyzed 
during the validation of the CrAg® LFA. Study flowchart of 
analyzed samples stored at the Medical and Experimental 
Mycology Group biobank. A total of 83 samples were tested, 
corresponding to 51 CSF and 32 sera
Figure 1 - Reactivity against Cryptococcus antigen: Comparison 
of the CrAg® LFA and the CALAS® tests. Analytical sensitivity 
of CrAg® LFA (light gray bars) and CALAS® (dark gray bars) are 
shown. The vertical axis shows the number of patients and the 
horizontal axis shows the final antigen titer
Table 1 - Analysis of concordance between CrAg® LFA and CALAS®





+ - + -
CrAg®LFA + 31 0 CrAg®LFA + 15 0
- 0 20 - 0 17
kappa index= 1.0; 95% CI = 1.0-1.0 kappa index= 1.0; 95% CI = 1.0-1.0
CSF: cerebrospinal fluid, 95% CI: 95% confidence interval, +: positive, -: negative
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LFA demonstrated higher analytical sensitivity to detect 
low concentrations of cryptococcal antigen compared with 
the CALAS® assay. This test could significantly reduce the 
time to diagnose and to treat cryptococcosis. 
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